Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

The American journal of tropical medicine and hygiene

Volumn 69, Issue 6 Suppl, 2003, Pages 48-60

  Edelman, Robert ^a   Wasserman, Steven S ^a   Bodison, Sacared A ^a   Putnak, Robert J ^a   Eckels, Kenneth H ^a   Tang, Douglas ^a   Kanesa Thasan, Niranjan ^a   Vaughn, David W ^a   Innis, Bruce L ^a   Sun, Wellington ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; VIRUS ANTIBODY; VIRUS DNA; VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS; SINGLE BLIND PROCEDURE; VACCINATION; VIREMIA;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; DNA, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SINGLE-BLIND METHOD; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES; VIREMIA;

MLCS; MLOWN;

EID: 1342310100     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2003.69.48     Document Type: Article

References (0)